2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma – An Indian experience
Authors:
- Jiten JaipuriaJJJiten Jaipuria
- Ankita JainAJAnkita Jain
- Shashikant GuptaSGShashikant Gupta
- Nripesh SadasukhiNSNripesh Sadasukhi
- Priyatham KasaraneniPKPriyatham Kasaraneni
- Amitabh SinghASAmitabh Singh
- Kush GuptaKGKush Gupta
- Girish SharmaGSGirish Sharma
- Vineet TalwarVTVineet Talwar
- Sudhir Kumar RawalSRSudhir Kumar Rawal
Open Access
- 1 October 2023
- journal article
- research article
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (4) , 493-500
Abstract
Background: Sunitinib remains the first-line treatment for favorable risk metastatic clear cell renal cell cancer (mccRCC). It was conventionally given in the 4/2 schedule; however, toxicity necessitated trying the 2/1 regimen. Regional variations in treatment response and toxicity are known, and there is no data from the Indian subcontinent about the outcomes of the alternative dosing schedule. Methods: Clinical records of all consecutive adult patients who received sunitinib as first-line therapy for histologically proven mccRCC following cytoreductive nephrectomy from 2010–2018 were reviewed. The primary objective was to determine the progression-free survival (PFS), and the secondary objectives were to evaluate the response rate (objective response rate and clinical benefit rate), toxicity, and overall survival. A list of variables having a biologically plausible association with outcome was drawn and multivariate inverse probability treatment weights (IPTW) analysis was done to determine the absolute effect size of dosing schedules on PFS in terms of “average treatment effect on the treated” and “potential outcome mean.” Results: We found 2/1 schedule to be independently associated with higher PFS on IPTW analysis such that if every patient in the subpopulation received sunitinib by the 2/1 schedule, the average time to progression was estimated to be higher by 6.1 months than the 4/2 schedule. We also found 2/1 group to have a lower incidence than the 4/2 group for nearly all ≥ grade 3 adverse effects. Other secondary outcomes were comparable between both treatment groups. Conclusion: Sunitinib should be given via the 2/1 schedule in Indian patients.Keywords
This publication has 26 references indexed in Scilit:
- Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinomaMedical Oncology, 2018
- Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital ExperienceClinical Genitourinary Cancer, 2017
- Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based StudyClinical Genitourinary Cancer, 2017
- Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysisActa Oncologica, 2016
- The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016European Urology, 2016
- RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trialAnnals of Oncology, 2015
- Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2015
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyThe Lancet Oncology, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCancer Chemotherapy and Pharmacology, 2007